Jinxin Fertility Group Limited reported solid operating growth for the six months ended 30 June 2026, underscored by broader patient reach, expanding service lines and robust overseas traction.

Core operating metrics • New patient visits for infertility (NPVs) increased 9.1% year on year to 24,169. • Oocyte pick-up (OPU) cycles rose 6.1% to 14,653.

Regional performance • Greater Bay Area led the expansion, with NPVs up 30.1% to 4,837 on the back of the new Shenzhen Zhongshan campus; OPU cycles edged 0.9% higher to 2,562. • Chengdu recorded marginal NPV growth of 0.6% to 10,601, but OPU cycles dipped 5.4% to 6,724 despite a 16.9% jump in third-generation IVF procedures. • Kunming & Wuhan saw mixed trends: NPVs slipped 4.5% to 4,178, while OPU cycles rose 15.4% to 2,377, reflecting improving brand recognition. • Overseas operations were the standout contributor—NPVs climbed 29.4% to 4,553 and OPU cycles hit 2,990, a 42.4% surge. Excluding the discontinued Laos unit, Huntington Reproductive Center in the U.S. delivered a 45.8% rise in cycles.

Strategic highlights • VIP client penetration continued to strengthen, up 0.9 ppts at Sichuan Jinxin Xinan’s Bisheng campus and 6.9 ppts at the newly opened Shenzhen Zhongshan facility. • Rapid expansion of IVF-related obstetrics services drove growth of more than 80%, broadening the Group’s women’s health value chain from “single delivery” to an integrated “maternity + reproductive” model. • Management reiterated alignment with national policies promoting fertility. Focus areas include widening access to third-generation IVF, integrating reproductive genetics and newborn screening, and extending offerings toward full-cycle health management.

The disclosed figures are unaudited and based on management’s preliminary assessment. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.